UNLIMITED TURBO SHORT - BOSTON SCIENTIFIC | Market Closed - Deutsche Boerse AG 15:50:32 2024-05-15 EDT | ||
| 0.61 EUR | -12.86% |
|
| Current month | -29.89% | ||
| 1 month | -51.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 0.61 | -12.86% |
| 24-05-14 | 0.7 | -7.89% |
| 24-05-13 | 0.76 | +8.57% |
| 24-05-10 | 0.7 | +6.06% |
| 24-05-09 | 0.66 | -14.29% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 03:50 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | 
BNP Paribas
|
| WKN | PN71QX |
| ISIN | DE000PN71QX5 |
| Date issued | 2023-08-31 |
| Strike | 80.76 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.41 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.06 € |
|---|---|
| Lowest since issue | 0.54 € |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
74.45
USD
Average target price
81.33
USD
Spread / Average Target
+9.24%
- Stock Market
- Certificates
- Certificat
